Overview & Mechanism Sertraline is an oral selective serotonin reuptake inhibitor (SSRI) primarily indicated for major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), social anxiety disorder, and premenstrual dysphoric disorder (PMDD). Its therapeutic effect results from selective serotonin reuptake blockade at the neuronal membrane, which directly increases serotonin availability and neural transmission.

Administration Guidelines Sertraline may be administered without regard to meals. Capsules must be swallowed whole. The oral liquid solution requires specialized handling: it must be mixed immediately before consumption with exactly 4 ounces of water, ginger ale, lemon-lime soda, lemonade, or orange juice only. The supplied dropper contains dry natural rubber, requiring caution in those with latex sensitivities.

Boxed Warnings & Severe Risks Sertraline carries a Boxed Warning regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 24 years of age. This risk is highest during treatment initiation and following dosage adjustments. Caregivers must vigilantly monitor for clinical worsening or behavioral changes. SSRI use in pediatric patients is also associated with potential growth inhibition, necessitating regular monitoring of height and weight. Other severe adverse reactions include serotonin syndrome, hyponatremia, gastrointestinal bleeding, and QT prolongation.

Dosing Framework

• Depression & OCD: The standard adult starting dose is 50 mg once daily, with a maximum dose of 200 mg/day. In pediatric populations, starting doses range from 12.5 mg to 25 mg daily based on age, gradually titrating while observing a maximum limit of 200 mg/day.
• Anxiety & PTSD: For panic disorder, PTSD, and social anxiety disorder, the typical adult initiation dose is 25 mg daily, increasing to 50 mg after one week, up to a maximum of 200 mg/day.
• PMDD: Dosing ranges from 50 to 150 mg daily, administered either continuously throughout the menstrual cycle or strictly during the luteal phase.
• Off-Label Uses: Includes hot flashes (50-100 mg/day), premature ejaculation (25-50 mg/day), pruritus, and binge-eating disorder.
• Organ Impairment: For patients with mild hepatic impairment, the daily dose must be reduced by 50%. Use in moderate or severe hepatic impairment is not recommended. Conversely, no dosage adjustments are required for renal impairment.

Adverse Effects The most commonly reported adverse effects are mild to moderate, including nausea (26%), diarrhea (20%), insomnia (20%), xerostomia (14%), fatigue (12%), and dizziness (12%). Sexual dysfunction is also highly prominent, presenting as ejaculation dysfunction, erectile dysfunction, and a general decrease in libido.

Pharmacokinetics Sertraline undergoes extensive first-pass metabolism in the liver via multiple CYP450 enzymes, primarily CYP2B6. It is highly protein-bound (98%) and exhibits an average elimination half-life of 26 hours. Clinically significant interactions can occur because sertraline inhibits the CYP2D6 isoenzyme in vivo, potentially requiring dose reductions for concurrent medications metabolized by this pathway.